Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study

Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study

Abstract Background Everolimus, an inhibitor of mammalian target of rapamycin (mTOR), has been shown to increase the efficacy of endocrine therapies in hormone receptor (HR)-positive metastatic breast cancer. However, because breast cancer is a highly heterogeneous disease, the responses of differen...

Full description

Bibliographic Details
Main Authors: Zongbi Yi, Fei Ma, Binliang Liu, Xiuwen Guan, Lixi Li, Chunxiao Li, Haili Qian, Binghe Xu
Format: Article
Language:English
Published: BMC 2019-05-01
Series:BMC Cancer
Subjects:
Biomarkers
Breast neoplasms
ctDNA
Everolimus
Online Access:http://link.springer.com/article/10.1186/s12885-019-5668-3

Internet

http://link.springer.com/article/10.1186/s12885-019-5668-3

Similar Items